SCHEDULE 13G: Ewon Comfortech Discloses 5.8% Stake in Liminatus Pharma Following Business Combination
Beneficial Ownership Disclosure
Ewon Comfortech Co., Ltd. has disclosed a 5.8% beneficial ownership stake in Liminatus Pharma, Inc., holding 1,500,000 shares of common stock following the consummation of a business combination on April 30, 2025.
Summary
- Ewon Comfortech Co., Ltd. reported beneficial ownership of 1,500,000 shares of Liminatus Pharma, Inc. common stock, par value $0.0001 per share.
- This ownership represents 5.8% of the total 26,014,633 shares of Common Stock outstanding upon the consummation of the business combination.
- The event requiring this filing occurred on April 30, 2025, which was the date of the business combination's consummation.
- Ewon Comfortech Co., Ltd. holds sole voting power and sole dispositive power over all 1,500,000 beneficially owned shares.
- The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Liminatus Pharma, Inc.
Sentiment
Score: 7
Explanation: The filing is a factual disclosure of a significant ownership stake. The acquisition of a 5.8% stake by an external entity, explicitly stating it is not for control purposes, can be interpreted as a positive vote of confidence in Liminatus Pharma, Inc. post-business combination.
Positives
- Ewon Comfortech Co., Ltd., a South Korean entity, has acquired a significant 5.8% stake in Liminatus Pharma, Inc., indicating a notable investment and potential vote of confidence in the company's post-business combination prospects.
- The acquisition of 1,500,000 shares demonstrates a substantial commitment from Ewon Comfortech Co., Ltd., providing a strong institutional shareholder base.
- The filing explicitly states that the stake is not for the purpose of changing or influencing control, suggesting a supportive, non-activist investment.
Negatives
- No explicit negatives are disclosed in this Schedule 13G filing, which primarily reports beneficial ownership and does not cover operational or financial performance.
Risks
- The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Liminatus Pharma, Inc., mitigating concerns about an activist or hostile takeover intent from this specific shareholder.
Future Outlook
This Schedule 13G filing primarily reports a beneficial ownership stake and does not contain forward-looking statements or guidance from Liminatus Pharma, Inc. regarding its future operations or financial performance.
Management Comments
- Ewon Comfortech Co., Ltd. certifies that, to the best of its knowledge and belief, the securities referred to were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.
Industry Context
The investment by Ewon Comfortech Co., Ltd., a South Korean entity, in Liminatus Pharma, Inc., a U.S. pharmaceutical company, highlights ongoing cross-border investment activity within the life sciences sector, particularly following significant corporate events like business combinations. This type of investment can signal international confidence in the growth potential of the U.S. biotech and pharma market.
Comparison to Industry Standards
- This Schedule 13G filing primarily reports a beneficial ownership stake and does not provide sufficient financial or operational details of Liminatus Pharma, Inc. to conduct a comprehensive comparison to industry standards or specific comparable companies' performance or valuation metrics.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor holding a 5.8% stake may provide increased confidence and potentially enhance liquidity for Liminatus Pharma, Inc.'s common stock.
- Management: The certification that the stake is not for control purposes suggests a supportive, rather than activist, investor, which could allow management to focus on strategic execution without immediate pressure from this shareholder.
Next Steps
- No specific future actions, events, or milestones for Liminatus Pharma, Inc. are detailed in this beneficial ownership filing, as it pertains to the reporting person's current ownership.
Key Dates
| Date | Description |
|---|---|
| November 30, 2022 | Date of the PIPE Equity Subscription Agreement and Lock-Up Agreement. |
| February 7, 2025 | Date of Form 424B3 filing by the Issuer with the SEC, incorporating by reference the PIPE Equity Subscription Agreement. |
| April 30, 2025 | Date of the event which required the filing of this statement (consummation of the Business Combination) and date of the Amended and Restated Registration Rights Agreement. |
| May 6, 2025 | Date of Form 8-K filing by the Issuer with the SEC, incorporating by reference the Amended and Restated Registration Rights Agreement and Lock-Up Agreement. |
| June 26, 2025 | Date the Schedule 13G was signed by Ewon Comfortech Co., Ltd. |
Keywords
Liminatus Pharma, Ewon Comfortech, Schedule 13G, beneficial ownership, common stock, business combination, SEC filing, investment, pharmaceutical, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.